Funds › Johnson & Johnson
Johnson & Johnson
13F for Q3 2026, filed Oct 26, 2026. 15 positions worth $761.7M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Johnson & Johnson in the latest 13F quarter?
Using 13F.ai, how has Johnson & Johnson's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Johnson & Johnson's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | PTGX Protagonist Therapeutics, Inc. | 2.45M | $345.1M | 45.3% | Unchanged | 13F ↗ |
| 2 | NBTX Nanobiotix S.A. · ADR | 5.62M | $175.2M | 23.0% | Unchanged | 13F ↗ |
| 3 | MGTX MeiraGTx Holdings plc | 6.64M | $73.1M | 9.6% | Unchanged | 13F ↗ |
| 4 | RAPP Rapport Therapeutics, Inc. | 1.78M | $60.0M | 7.9% | Unchanged | 13F ↗ |
| 5 | CTNM Contineum Therapeutics, Inc. | 1.98M | $26.6M | 3.5% | Unchanged | 13F ↗ |
| 6 | CBRS Cerebras Systems Inc. | 128,649 | $22.9M | 3.0% | +140% | 13F ↗ |
| 7 | XNCR Xencor, Inc. | 748,062 | $18.7M | 2.5% | Unchanged | 13F ↗ |
| 8 | LEGN Legend Biotech Corporation · ADR | 814,586 | $16.2M | 2.1% | Unchanged | 13F ↗ |
| 9 | FATE Fate Therapeutics, Inc. | 3.38M | $8.0M | 1.1% | Unchanged | 13F ↗ |
| 10 | CVRX CVRx, Inc. | 4.02M | $7.0M | 0.9% | Unchanged | 13F ↗ |
| 11 | PRCT PROCEPT BioRobotics Corporation | 357,939 | $6.5M | 0.9% | Unchanged | 13F ↗ |
| 12 | NMRA Neumora Therapeutics, Inc. | 1.85M | $1.1M | 0.1% | Unchanged | 13F ↗ |
| 13 | VOR Vor Biopharma Inc. | 53,732 | $1.0M | 0.1% | Unchanged | 13F ↗ |
| 14 | LAB Standard BioTools Inc. | 311,967 | $231.0K | <0.1% | Unchanged | 13F ↗ |
| 15 | ACET Adicet Bio, Inc. | 22,779 | $162.6K | <0.1% | Unchanged | 13F ↗ |
Changes since Q2 2026
0 new, 1 added to, 0 trimmed, 0 exited, 14 unchanged. By estimated dollars.
New positions (0)
None this quarter.
Added to (1)
| Position | Shares | Change | Est. dollars |
|---|---|---|---|
| CBRS Cerebras Systems Inc. | 128,649 | +140% | $13.3M |
Trimmed (0)
None this quarter.
Exited (0)
None this quarter.
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Oct 26, 2026 | 13F-HR | 15 | $761.7M | Current | SEC ↗ |
| Q2 2026 | Aug 6, 2026 | 13F-HR | 15 | $798.7M | Current | SEC ↗ |
| Q1 2026 | May 13, 2026 | 13F-HR | 16 | $652.4M | Current | SEC ↗ |
| Q4 2025 | Mar 18, 2026 | 13F-HR/A (restatement) | 17 | $555.0M | Current | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 17 | $554.6M | Replaced | SEC ↗ |
| Q3 2025 | Mar 18, 2026 | 13F-HR/A (restatement) | 20 | $503.9M | Current | SEC ↗ |
| Q3 2025 | Nov 13, 2025 | 13F-HR | 20 | $503.7M | Replaced | SEC ↗ |
| Q2 2025 | Jul 22, 2025 | 13F-HR | 20 | $334.1M | Current | SEC ↗ |
| Q1 2025 | May 7, 2025 | 13F-HR | 20 | $341.9M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer